The combination of a $3M dilutive offering, massive warrant overhang (200% coverage), and a $150M shelf filed just 9 days prior signals severe capital needs. With a $9M market cap and no analyst support, the stock faces significant downward pressure. Monitor for further dilution under the shelf and any Nasdaq compliance issues (minimum bid price).
Price Chart
Executive Summary
Co-Diagnostics entered into a securities purchase agreement to raise $3M through the sale of common shares, pre-funded warrants, and common warrants at a purchase price of $1.8210 per share, with the common warrants exercisable at $1.5710 for 5 years and covering 200% of the shares/warrants purchased. The offering follows a $150M shelf filing from 9 days prior and represents extreme dilution relative to the company's $9M market cap, with the common warrants alone adding potential dilution of up to ~$6M in notional value. Proceeds are for working capital and general corporate purposes.
Key Financial Metrics
Key Facts
- Company raised $3M via private placement at $1.8210/share, a ~7% discount to the $1.96 closing price implied by the $1.5710 warrant exercise price
- Investors received common warrants exercisable at $1.5710 for 5 years, covering 200% of the shares/warrants purchased, creating massive future dilution potential
- The offering follows a $150M universal shelf filing (S-3) from May 12, 2026, representing over 20x the company's $9M market cap
- Proceeds are for working capital and general corporate purposes, with no specific use disclosed
- Company has a 60-day lock-up on further equity issuance and 90-day ban on variable rate transactions from the effective date of the resale registration statement
- Market cap is only $9M with 0% analyst bullish rating (4 Hold, 1 Sell, 2 Strong Sell)
Financial Impact
$3M gross proceeds, but warrants could add up to ~$6M in additional dilution if exercised; total potential dilution exceeds 100% of current shares outstanding
Risk Factors
- Extreme dilution from the $150M shelf and the 200% warrant coverage could overwhelm existing shareholders
- Nasdaq minimum bid price compliance risk (company previously disclosed notice in July 2025)
- Proceeds used for working capital suggest ongoing cash burn without clear revenue catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024738 |
| Exhibit: ex10-2.htm | 0001493152-26-024738 |
| Exhibit: ex4-2.htm | 0001493152-26-024738 |
| Exhibit: ex4-1.htm | 0001493152-26-024738 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEF 14A | $0.5473 | awaiting T+20 | — | $0.4640 (+15.22%) |
Oct 15, 2026 12d ago | 8-K/A | $0.7151 | awaiting T+20 | — | $0.4640 (+35.11%) |
Oct 13, 2026 14d ago | 8-K | $1.07 | awaiting T+20 | — | $0.4640 (+56.43%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4640 (−50.68%) |
Sep 16, 2026 5w ago | 8-K | $0.9408 $1.07 | ▲ +13.20% | ▲ +10.02% | $0.4640 (−50.68%) |
Sep 4, 2026 7w ago | DEFA14A | $1.16 $1.10 | ▼ −5.17% | ▼ −5.77% | $0.4640 (−60.00%) |
Sep 2, 2026 7w ago | EFFECT | $1.16 $1.07 | ▲ +7.76% | ▲ +7.68% | $0.4640 (+60.00%) |
Jul 31, 2026 12w ago | 8-K | $1.44 $1.21 | ▲ +15.97% | ▲ +18.96% | $0.4640 (+67.78%) |
Jul 27, 2026 13w ago | 424B5 | $1.41 $1.23 | ▲ +12.77% | ▲ +16.15% | $0.4640 (+67.09%) |
Jun 1, 2026 21w ago | EFFECT | $6.20 $3.10 | ▲ +50.00% | ▲ +48.70% | $0.4640 (+92.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers